Arteris VP, GC granted 32,385 RSUs
Alpern Paul L reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alpern Paul L reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. reported that its VP and General Counsel, Paul L. Alpern, received an equity award of 32,385 restricted stock units (RSUs), each representing one share of common stock, at no cash cost per share. These RSUs will vest as to 1/16 of the total on April 1, 2026, then in equal quarterly installments thereafter, and have no expiration date. Following this grant, Alpern beneficially owns 90,035 shares of common stock, including the 32,385 RSUs.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 32,385 | $0.00 | $0.00 |
Footnotes (1)
- F1. Includes 32,385 restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest with respect to 1/16th of the total RSUs on 4/1/2026 and in equal quarterly installments thereafter. The RSUs have no expiration date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Arteris (AIP) report for Paul L. Alpern?
What are the vesting terms of the 32,385 RSUs granted by Arteris (AIP)?
Do the Arteris (AIP) RSUs granted to Paul L. Alpern have an expiration date?
Was the Arteris (AIP) RSU grant to Paul L. Alpern a market purchase?
AI-generated analysis. How Rhea-AI works. Not financial advice.